TY - JOUR
T1 - Energy transfer in "parasitic" cancer metabolism
T2 - Mitochondria are the powerhouse and Achilles' heel of tumor cells
AU - Martinez-Outschoorn, Ubaldo E.
AU - Pestell, Richard G.
AU - Howell, Anthony
AU - Tykocinski, Mark L.
AU - Nagajyothi, Fnu
AU - Machado, Fabiana S.
AU - Tanowitz, Herbert B.
AU - Sotgia, Federica
AU - Lisanti, Michael P.
N1 - Funding Information:
function in cancer cells sensitizes them tDo noto dsitribute. chemotherapy, resulting in a good clini- cal response and increased overall survival Q. Landenberger Research Foundation. Nacional de Desenvolvimento Científico e in cancer patients. As such, mitochon-M.P.L. was supported by grants from Tecnológico (CNPq) [# 576200/2008-5, drial dysfunction (i.e., the conventional the NIH/NCI (R01-CA-080250; #473670/2008-9], and the Fundação de Warburg effect) in tumor cells predicts R01-CA-098779; R01-CA-120876; Amparo à Pesquisa do Estado de Minas chemo-sensitivity in cancer patients, R01-AR-055660), and the Susan G. Gerais (FAPEMIG) [#14916]. H.B.T. was whereas mitochondrial “health and well-Komen Breast Cancer Foundation. R.G.P. funded by NIH grant AI-76248. being” in cancer cells (i.e., indicative of was supported by grants from the NIH/ “Parasitic Cancer Metabolism”) predicts NCI (R01-CA-70896, R01-CA-75503, chemo-resistance. These clinical find-R01-CA-86072 and R01-CA-107382) and ings directly support our new paradigm, the Dr. Ralph and Marian C. Falk Medical which is based on (1) mitochondrial func-Research Trust. The Kimmel Cancer tion and (2) energy transfer in cancer Center was supported by the NIH/NCI metabolism. Cancer Center Core grant P30-CA-56036 For further details, please see: (to R.G.P.). Funds were also contributed by Chonghaile TN, Sarosiek KA, Vo TT, the Margaret Q. Landenberger Research Ryan JA, Tammareddi A, Moore VD, Foundation (to M.P.L.). This project is et al. Pretreatment mitochondrial prim-funded, in part, under a grant with the ing correlates with clinical response to Pennsylvania Department of Health (to cytotoxic chemotherapy. Science 2011; M.P.L. and F.S.). The Department spe- 334:1129-33; PMID:22033517. cifically disclaims responsibility for any
PY - 2011/12/15
Y1 - 2011/12/15
N2 - It is now widely recognized that the tumor microenvironment promotes cancer cell growth and metastasis via changes in cytokine secretion and extracellular matrix remodeling. However, the role of tumor stromal cells in providing energy for epithelial cancer cell growth is a newly emerging paradigm. For example, we and others have recently proposed that tumor growth and metastasis is related to an energy imbalance. Host cells produce energy-rich nutrients via catabolism (through autophagy, mitophagy and aerobic glycolysis), which are then transferred to cancer cells, to fuel anabolic tumor growth. Stromal cell derived L-lactate is taken up by cancer cells and is used for mitochondrial oxidative phosphorylation (OXPHOS), to produce ATP efficiently. However, "parasitic" energy transfer may be a more generalized mechanism in cancer biology than previously appreciated. Two recent papers in Science and Nature Medicine now show that lipolysis in host tissues also fuels tumor growth. These studies demonstrate that free fatty acids produced by host cell lipolysis are re-used via β-oxidation (β-OX) in cancer cell mitochondria. Thus, stromal catabolites (such as lactate, ketones, glutamine and free fatty acids) promote tumor growth by acting as high-energy onco-metabolites. As such, host catabolism, via autophagy, mitophagy and lipolysis, may explain the pathogenesis of cancer-associated cachexia, and provides exciting new druggable targets for novel therapeutic interventions. Taken together, these findings also suggest that tumor cells promote their own growth and survival by behaving as a "parasitic organism."Hence, we propose the term "parasitic cancer metabolism" to describe this type of metabolic-coupling in tumors. Targeting tumor cell mitochondria (OXPHOS and β-OX) would effectively uncouple tumor cells from their hosts, leading to their acute starvation. In this context, we discuss new evidence that high-energy onco-metabolites (produced by the stroma) can confer drug resistance. Importantly, this metabolic chemo-resistance is reversed by blocking OXPHOS in cancer cell mitochondria, with drugs like Metformin, a mitochondrial "poison." In summary, parasitic cancer metabolism is achieved architecturally by dividing tumor tissue into at least two well-defined opposing "metabolic compartments:" catabolic and anabolic.
AB - It is now widely recognized that the tumor microenvironment promotes cancer cell growth and metastasis via changes in cytokine secretion and extracellular matrix remodeling. However, the role of tumor stromal cells in providing energy for epithelial cancer cell growth is a newly emerging paradigm. For example, we and others have recently proposed that tumor growth and metastasis is related to an energy imbalance. Host cells produce energy-rich nutrients via catabolism (through autophagy, mitophagy and aerobic glycolysis), which are then transferred to cancer cells, to fuel anabolic tumor growth. Stromal cell derived L-lactate is taken up by cancer cells and is used for mitochondrial oxidative phosphorylation (OXPHOS), to produce ATP efficiently. However, "parasitic" energy transfer may be a more generalized mechanism in cancer biology than previously appreciated. Two recent papers in Science and Nature Medicine now show that lipolysis in host tissues also fuels tumor growth. These studies demonstrate that free fatty acids produced by host cell lipolysis are re-used via β-oxidation (β-OX) in cancer cell mitochondria. Thus, stromal catabolites (such as lactate, ketones, glutamine and free fatty acids) promote tumor growth by acting as high-energy onco-metabolites. As such, host catabolism, via autophagy, mitophagy and lipolysis, may explain the pathogenesis of cancer-associated cachexia, and provides exciting new druggable targets for novel therapeutic interventions. Taken together, these findings also suggest that tumor cells promote their own growth and survival by behaving as a "parasitic organism."Hence, we propose the term "parasitic cancer metabolism" to describe this type of metabolic-coupling in tumors. Targeting tumor cell mitochondria (OXPHOS and β-OX) would effectively uncouple tumor cells from their hosts, leading to their acute starvation. In this context, we discuss new evidence that high-energy onco-metabolites (produced by the stroma) can confer drug resistance. Importantly, this metabolic chemo-resistance is reversed by blocking OXPHOS in cancer cell mitochondria, with drugs like Metformin, a mitochondrial "poison." In summary, parasitic cancer metabolism is achieved architecturally by dividing tumor tissue into at least two well-defined opposing "metabolic compartments:" catabolic and anabolic.
KW - Aerobic glycolysis
KW - Autophagy
KW - Beta-oxidation
KW - Cancer metabolism
KW - Chemo-resistance
KW - Drug discovery
KW - Drug resistance
KW - Lipolysis
KW - Metabolic compartments
KW - Metformin
KW - Mitochondria
KW - Mitophagy
KW - Oncometabolite
KW - Oxidative phosphorylation
KW - Parasite
KW - Warburg effect
UR - http://www.scopus.com/inward/record.url?scp=84055190706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84055190706&partnerID=8YFLogxK
U2 - 10.4161/cc.10.24.18487
DO - 10.4161/cc.10.24.18487
M3 - Review article
C2 - 22033146
AN - SCOPUS:84055190706
SN - 1538-4101
VL - 10
SP - 4208
EP - 4216
JO - Cell Cycle
JF - Cell Cycle
IS - 24
ER -